Advertisement
Including Sodium Cromoglicate Eye Drops and Ftibamzone Liniment, China SkyOne Medical has now received SFDA approval for a total of 15 new drugs in 2008.
Advertisement
"We are proud to have obtained production approval for 15 new drugs in2008 and see this as an outstanding achievement for China Sky One," said Mr.Yan-Qing Liu, Chairman and CEO of China Sky One Medical. "These drugs treat avariety of illnesses and we are excited about their market potential. We areconfident that strong results from our R&D efforts will lead to more drugapprovals in 2009, which will further enhance our sales performance."
About China Sky One Medical, Inc.
China Sky One Medical, Inc., a Nevada corporation, is a holding company.The Company engages in the manufacturing, marketing and distribution ofpharmaceutical, medicinal and diagnostic products. Through its wholly-ownedsubsidiaries, Harbin Tian Di Ren Medical Science and Technology Company("TDR"), Harbin First Bio-Engineering Company Limited ("First"), HeilongjiangTianlong Pharmaceutical, Inc. ("Tianlong") and Peng Lai Jin Chuang CompanyPharmaceutical Company ("Jin Chuang") the Company manufactures and distributesover-the-counter pharmaceutical products, which make up its major revenuesource. For more information, visit http://www.skyonemedical.com .
Safe Harbor Statement
Certain of the statements made in the press release constituteforward-looking statements within the meaning of the Private SecuritiesLitigation Reform Act of 1995. These statements can be identified by the useof forward- looking terminology such as "believe," "expect," "may," "will,""should," "project," "plan," "seek," "intend," or "anticipate" or the negativethereof or comparable terminology. Such statements typically involve risks anduncertainties and may include financial projections or information regardingour future plans, objectives or performance. Actual results could differmaterially from the expectations reflected in such forward-looking statementsas a result of a variety of factors, including the risks associated with theeffect of changing economic conditions in The People's Republic of China,variations in cash flow, reliance on collaborative retail partners and on newproduct development, variations in new product development, risks associatedwith rapid technological change, and the potential of introduced or undetectedflaws and defects in products, and other risk factors detailed in reportsfiled with the Securities and Exchange Commission from time to time.-- Sodium Ferulate injection for the treatment of cardiovascular disease; -- Compound Naphazoline spray is for the treatment of rhinopathy; -- Naphazoline Hydrochloride Chlorpheniramine Maleate and Benzalkonium Bromide spray for the treatment of rheumatic diseases; -- Doxofylline injection for the treatment of asthma and bronchitis; -- Oxymetazoline Hydrochloride nasal drops for the treatment of acute and chronic rhinitis, sinusitis and allergic rhinitis; -- Taurine eye drops for the treatment of acute and chronic conjunctivitis; -- Tobramycin eye drops for the treatment of acute infection on eyelids; -- Compound Zinc Sulfate eye drops for the treatment of acute and chronic conjunctivitis and trachoma; -- Ofloxacin suppositories for the treatment for bactericidal vaginitis and Oflcoxacin gel for the treatment of bactericidal colpitis; -- Nasal drops for the treatment of allergic rhinitis and sinusitis; -- Tinea Liniment for the treatment of athlete's foot (tinea pedis), hand ringworm (tinea manus), jock itch (tinea cruris) and fungal skin infection (tinea versicolor); and -- Skincare cream for the treatment of skin diseases such as acne, bottle nose, chromophytosis and vitiligo.
SOURCE China Sky One Medical, Inc.